Efficacy and Tolerability of Peginterferon α-2a and Peginterferon α-2b, Both plus Ribavirin, for Chronic Hepatitis C: A Meta-Analysis of Randomized Controlled Trials

Table 1

Baseline characteristics of the included trials in this meta-analysis.

Study	Peginterferon	Ribavirin	Baseline treatment history	HCV genotype	Treatment in weeks	Country	Publication year	Study type
Yenice et al. [5]	α-2a 180 ug/week; α-2b 1.5 ug/kg/week	800–1200 mg/day	Naïve	1	24 or 48	Turkey	2006	RCT
Di Bisceglie et al. [6]	α-2a 180 ug/week; α-2b 1.5 ug/kg/week	1000–1200 mg/day	Naïve	1	12	USA	2007	RCT
Scotto et al. [7]	α-2a 180 ug/week; α-2b 1.5 ug/kg/week	15 mg/kg/day	Nonresponders	1,2,3,4	48	Italy	2008	RCT
McHutchison et al. [8]	α-2a 180 ug/week; α-2b 1.5 ug/kg/week	800–1400 mg/day	Naïve	1	24 or 48	IDEAL study team	2009	RCT
Rumi et al. [9]	α-2a 180 ug/week; α-2b 1.5 ug/kg/week	800–1200 mg/day	Naïve	1,2,3,4	24 or 48	Italy	2010	RCT
Ascione et al. [10]	α-2a 180 ug/week; α-2b 1.5 ug/kg/week	1000–1200 mg/day	Naïve	1,2,3,4	24 or 48	Italy	2010	RCT
Mach et al. [11]	α-2a 180 ug/week; α-2b 1.5 ug/kg/week	1000–1200 mg/day	Naïve	1b	48	Poland	2011	RCT